Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Children’s cancer death rates drop by 24% in last decade
The latest figures show death rates for all cancers in children aged 14 and under have fallen from around 30 deaths per million in 2004 to almost 23
The latest figures show death rates for all cancers in children aged 14 and under have fallen from around 30 deaths per million in 2004 to almost 23
Solasia will retain rights to promote Sancuso in three major cities (Beijing, Shanghai and Guangzhou; the "Retained Territory") in the PRC. Under the terms of the Agreement, Solasia
The study aims to cut the rate of re-operations in breast cancer, potentially preventing many thousands of women globally from facing additional surgery, and providing significant cost savings
Fluad is the first adjuvanted seasonal influenza vaccine approved in the United States; it was specifically developed for the adult population aged 65 and older. Fluad is an
The expansion will provide additional office space and development services capacity to meet the growing demands of the pharmaceutical and biotechnology markets. The Wilmington site expansion will provide
The review of this application was conducted under the centralized licensing procedure as a therapeutic innovation, and is applicable in all 28 member states of the European Union,
Amgen believes this submission is the first adalimumab biosimilar application submitted to the FDA and represents Amgen’s first BLA submission using the 351(k) biosimilar pathway. Amgen executive vice
The two companies will collaborate on conducting clinical trials in Russia. Biosequel founder and practicing Israeli physician Vitaly Shabadash said: "We have searched the world over for a
Adaptimmune is developing the affinity enhanced T-cell therapy targeting NY-ESO-1 under a collaboration agreement with GlaxoSmithKline (GSK). Adaptimmune chief medical officer Rafael Amado said: "Lung cancer is the
The application submitted for the treatment of primary immunodeficiency diseases (PID), a class of inherited genetic disorders that causes an individual to have a deficient or absent immune